We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Potential for reducing resting sympathetic nerve activity with new classes of glucose-lowering drugs in heart failure with preserved ejection fraction.
- Authors
Washio, Takuro; Hissen, Sarah L.; Takeda, Ryosuke; Akins, John D.; Wakeham, Denis J.; Brazile, Tiffany; Hearon Jr, Christopher M.; MacNamara, James P.; Sarma, Satyam; Levine, Benjamin D.; Fadel, Paul J.; Fu, Qi
- Abstract
A small pilot study published in Clinical Autonomic Research suggests that new classes of glucose-lowering drugs, such as glucagon-like peptide 1 receptor agonists (GLP1ra) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), may reduce resting sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF). HFpEF is associated with high morbidity, mortality, and economic cost, and current drug therapies have limited success in improving outcomes. The study compared resting muscle sympathetic nerve activity (MSNA) in patients with HFpEF taking GLP1ra or SGLT2i to those not taking these drugs and found that the drug group had significantly lower MSNA. The mechanisms behind this reduction in sympathetic activity are still unknown, and further research is needed to fully understand the impact of these drugs on sympathetic neural control in HFpEF patients.
- Subjects
HEART failure; VENTRICULAR ejection fraction; SODIUM-glucose cotransporter 2 inhibitors
- Publication
Clinical Autonomic Research, 2024, Vol 34, Issue 1, p223
- ISSN
0959-9851
- Publication type
Article
- DOI
10.1007/s10286-023-01013-0